Celltrion Inc., of Incheon, South Korea, said Australia's Therapeutic Goods Administration approved its infliximab biosimilar Remsima. However, the follow-on, which references immunology drug Remicade (Johnson & Johnson), isn't likely to launch for several months, as it will take about half a year to set the price for the Australian market, Benjamin Chang, assistant manager of Celltrion's investor relations team, told BioWorld Asia.